Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have not taken the following treatments within the indicated duration and agree not to use at any time during the study:~  * All other Benign Prostatic Hyperplasia (BPH) therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.~ * Overactive bladder therapy (including antimuscarinics) for at least 4 weeks prior to receiving study medication.~ * Erectile Dysfunction therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication.~ * Finasteride or dutasteride use at any time.~* Have bladder outlet obstruction as defined by a urinary peak flow rate (Qmax) of greater than or equal to 4 and less than or equal to 15 milliliters (mL)/second before receiving study drug.~* Have prostate enlargement measured by ultrasound at screening.~Exclusion Criteria:~* Have prostate cancer, are being treated for cancer or have clinical evidence of prostate cancer \[Prostate-specific antigen (PSA) greater than 10 nanograms/milliliter (ng/mL) at the start of study\].~* Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).~* Have problems with kidneys, liver, or nervous system~* Have uncontrolled diabetes~* Have had a stroke or a significant injury to brain or spinal cord.~* Have scheduled or planned surgery during the course of the study.

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).